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Abstract
Infections of Streptococcus pneumoniae in children can be prevented by vaccination; left untreated, they cause high
morbidity and fatalities. This study aimed at determining the nasopharyngeal carrier rates, serotype distribution and
antimicrobial resistance patterns of S. pneumoniae in healthy Palestinian children under age two prior to the full
introduction of the pneumococcal 7-valent conjugate vaccine (PCV7), which was originally introduced into Palestine in a
pilot trial in September, 2010. In a cross sectional study, nasopharyngeal specimens were collected from 397 healthy
children from different Palestinian districts between the beginning of November 2012 to the end of January 2013. Samples
were inoculated into blood agar and suspected colonies were examined by amplifying the pneumococcal-specific autolysin
gene using a real-time PCR. Serotypes were identified by a PCR that incorporated different sets of specific primers.
Antimicrobial susceptibility was measured by disk diffusion and MIC methods. The resulting carrier rate of Streptococcus
pneumoniae was 55.7% (221/397). The main serotypes were PCV7 serotypes 19F (12.2%), 23F (9.0%), 6B (8.6%) and 14 (4%)
and PCV13 serotypes 6A (13.6%) and 19A (4.1%). Notably, serotype 6A, not included in the pilot trial (PCV7) vaccine, was the
most prevalent. Resistance to more than two drugs was observed for bacteria from 34.1% of the children (72/211) while
22.3% (47/211) carried bacteria were susceptible to all tested antibiotics. All the isolates were sensitive to cefotaxime and
vancomycin. Any or all of these might impinge on the type and efficacy of the pneumococcal conjugate vaccines and
antibiotics to be used for prevention and treatment of pneumococcal disease in the country.
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Introduction
Pneumococcal infection caused by Streptococcus pneumoniae is a
major contributor to morbidity and the main cause of deaths
preventable by vaccination in children under age five worldwide
[1,2]. The World Health Organization (WHO) estimates that
more than one million children die of pneumococcal disease in
developing countries every year [3]. The range of pneumococcal
infections is wide and often preceded by an asymptomatic carrier
state, in the nasopharynx, mainly in pre-school children [4]. The
presence of S. pneumoniae in the nasopharynx of healthy children is
indicative of the strains circulating and causing infections in the
community, and has often been reported as being a precursor to
waves of invasive disease and a major factor in the spread of
infection [5–7].
Currently, more than 90 distinct serotypes of S. pneumoniae have
been described, based on the structure of the capsular polysac-
charides, which are considered to be the major virulence factors
[8–10]. Only some of the serotypes cause disease and, of those that
do, some have a greater capacity to invade and cause bacterae-
mias. Others are more frequently associated with respiratory tract
disease without a bacteraemia, while still others remain limited to
the nasopharynx, bacteria lacking a polysaccharide capsule rarely
cause invasive disease [11].
Prevention of infections caused by S. pneumoniae and their spread
in young children is such an important goal of effective vaccination
that new vaccines have been developed to achieve this. In 2007,
the WHO recommended that pneumococcal conjugate vaccine 7
(PCV7), which contains the polysaccharides of the serotypes 4, 6B,
9V, 14, 18C, 19F and 23F, be used in national immunization
programs (NIP) [3]. Two more PCVs were recently introduced:
PCV10, which contains the polysaccharides of the serotypes 1, 5,
and 7F in addition to the serotypes of PCV7, and PCV13, which
contains the polysaccharides of the serotypes 3, 6A, and 19A in
addition to the serotypes of PCV10 [12,13]. PCVs of higher
valence provide broader serotype coverage [14,15]. The use of
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PCVs in young children creates herd immunity by reducing
transmission and, thus, circulation of the bacterial serotypes
opposed by the vaccine, leading to a decrease in invasive
pneumococcal disease (IPD) in the population [16,17].
Treatment of pneumococcal infections is becoming more
difficult owing to the emergence of antibiotic-resistant pneumo-
cocci. Studies on serotype distribution and their antibiotic
sensitivities are necessary for planning rational national strategies
for preventing and treating IPD [6]. Surveillance of pneumococcal
diseases according to bacterial serotypes is essential, to learn about
the current serotype distribution and to observe the efficacy of
PCVs by following the dynamics of bacterial serotypes in the
population, following the introduction of vaccination. Several
studies have reported regional and temporal changes in the
distribution of bacterial serotypes after the application of PCVs
[18,19].
Kattan et al. [20] described the distribution of invasive S.
pneumoniae from two Palestinian hospitals where bacteria of
serotypes 6, 14, 1, and 9V predominated. The serotypes within
serogroup 6 were not determined, however, it is important to
identify the serotypes within serogroups such as serogroup 6 as
serotype 6B polysaccharide is in PCV7 while serotypes 6A and 6C
are not.
Following an introductory trial of the PCV7 vaccine in a pilot
study in the Hebron, Bethlehem, Jericho and Tubas districts in
September 2010, this study was done to determine the rate of
nasopharyngeal pneumococcal infection in healthy children,
identify the serotypes of the circulating strains of S. pneumoniae
and determine their antibiotic susceptibilities.
Materials and Methods
In this cross-sectional study, 197 female and 200 male healthy
children more than two years old, attending the West Bank
primary health care centers was examined. The children were
selected according to their vaccination cards and distribution in
different regions per district such that the number of participants
per district was proportional to the size of the district population.
Health workers contacted parents using the phone number
inscribed on vaccination cards. The study was conducted from
November 2012 through January 2013. After obtaining informed
parental written consent, members of the study team examined
each child and documented relevant data on a pre-designed
questionnaire that requested the age, gender, district, location of
residence, and whether the child had been vaccinated with PCV7
or not, and, if vaccinated, giving the number of doses. The Ethics
Research Committee of Al-Quds University and Palestinian
Ministry of Health in Ramallah approved all the study activities,
including the written informed consent. Nasopharyngeal speci-
mens were taken in the health care centers by a well-trained
physician, who used extra-thin flexible flocked swabs, which were
immediately transferred into Amies transport media tubes (Copan
Diagnostics Inc, Murrieta, CA, USA) that were transported to the
Central Public Health Laboratory (CPHL) in Ramallah within 2 h
for the isolation, identification, serotyping and in vitro testing of
antimicrobial susceptibility of S. pneumoniae.
Pneumococcal isolate detection and identification
On arrival at the CPHL, swabs were streaked onto plates
containing 5% sheep blood and 5 mg/ml gentamicin (Fluka).
Plates were incubated for 18 to 24 h at 37uC in candle jars.
Potential colonies of S. pneumoniae were carefully selected by
colonial morphology and alpha-hemolysis, and confirmed by
Gram staining and susceptibility to optochin (Himedia Laborato-
ries Pvt. Ltd, India) (inhibition zone .14 mm). Samples were also
examined with a Real Time PCR-based method for the
pneumococcal-specific autolysin gene (lytA), of which the primer
and probe sequences were as described by McAvin et al. [21].
The same nasopharyngeal flocked swabs were also inoculated
into cryotubes containing 1.0 ml of skim milk, tryptone, glucose,
glycerol (STGG) transport medium. To store isolates, each
recovered pneumococcal isolate was sub-cultured on blood agar.
The single colonies were then removed using sterile cotton swabs
and, put into labelled cryotubes containing 1.0 ml STGG
medium, and stored at 270uC until tested for serotype and
antimicrobial susceptibility. Cultures were also lyophilized in
skimmed milk and stored at 270uC.
In vitro susceptibility testing
Testing the susceptibility of the strains of S. pneumoniae to
penicillin (oxacillin) (1 mg), erythromycin (15 mg), trimethoprim–
sulfamethoxazole (25 mg) and vancomycin (30 mg) (Oxoid Ltd,
UK) was done according to Kirby Bauer, using a disk diffusion
method on Mueller Hinton agar enriched with 5% sheep blood.
Susceptibility to penicillin was also determined by E-test Antimi-
crobial Minimum Inhibitory Concentrations (MICs) as it was for
cefotaxime. MICs and Disk Diffusion breakpoints used in this
study were interpreted according to Clinical Laboratory Standards
Institute (CLSI) guidelines [22]. All isolates of S. pneumoniae
suspected of being penicillin resistant (oxacillin susceptibility: disk
diffusion method ,20 mm) were tested further for penicillin MICs
by the E-test strip method according to the manufacturer’s
instructions (Oxoid). Penicillin G and Cefotaxime strains of S.
pneumoniae were defined as isolates with a MIC $2 mg/ml as
resistant, 0.12 mg/ml as intermediate resistance, and#0.06 mg/ml
as susceptible.
DNA extraction
Streptococcal DNA was extracted from the cultured bacteria
using the CDC protocol (http://www.cdc.gov/ncidod/biotech/
strep/pcr.htm).
Real-time PCR for lytA. The real-time PCR assay was
carried out on a final reaction volume of 25 ml and performed using
Eurogentec qPCR Master Mix (Eurogentec, Seraing, Belgium),
containing low ROX as a passive reference, according to the
manufacturer instructions, and 5 ml of DNA sample was used in
each reaction. The primers and probe concentrations were 0.2 mM
for each one. No template control (NTC) and S. pneumoniae-positive
DNA control were included in each run. Amplification was done in
the 7500 Real Time PCR system (Applied Biosystems) under the
following PCR conditions: 95uC for 10 min, followed by 40 cycles
of 95uC for 15 s and 60uC for 1 min.
Capsular Serotyping
Serotyping of the isolates of S. pneumoniae was performed by a
sequential multiplex PCR assay, using a set of primers targeting
different serotype specific sequences as described by Pai et al [23].
The serotypes tested included 1, 3, 4, 5, 6A/B/C/D, 7C/7B/40,
7F/7A, 9V/9A, 9N/9L, 10A, 11A/11D, 12F/12A/44/46, 13, 14,
15A/15F, 15B/15C, 18 (A/B/C/F), 19A, 19F, 20, 21, 22F/22A,
23A, 23F, 24(A/B/F), 33F/33A/37, 34, 35B, 35F/47F, 38/25F/
25A. All other serotypes were classified as nontypeable.
Differentiation of the serogroup subtypes 6A/C and 6B of
S. pneumoniae
Forty-nine isolates identified by the sequential multiplex PCR
assay of S. pneumoniae belonged to the serogroup 6. It was
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important to identify the subtype 6A/C of the serogroup 6 since it
is not included in the PCV7 vaccine. In addition, the published
method for differentiating serogroup 6 subtypes requires a
laborious and sophisticated effort so we introduced the restriction
fragment length polymorphism (RFLP) method to distinguish
serotype 6A/C from serotype B. The PCR method described by
Jin et al. [24] to reveal sub-serotype specificity, using G584A
polymorphism as a target, did not expose the specificity they
described in our hands.
The universal reverse primer (wciP-r) of Jin et al. [24] was used.
The new forward primer (ForSeq) given below was designed to
amplify the region covering the entire single nucleotide polymor-
phism (SNP) and was used for RFLP analysis. Twenty-eight PCR-
amplification samples of serogroup 6 were sent for sequencing
using the wciP-r primer [24] and also using our own newly
designed primer ForSeq: 59 TGG GGA TTG AAT TAC CGA
AC).
PCR amplification of the 28 samples was as follows: The final
reaction volume of 50 ml contained DreamTaq Green PCR
Master Mix (Thermo Scientific), 0.25 mM of each primer, and 5 ml
of DNA template. Thermocycler conditions for amplification
were: 95uC for 15 min, 35 cycles of 94uC for 30 s, 62uC for 60 s,
and 72uC for 60 s, and a final extension of 72uC for 10 min
followed by a hold at 4uC. By Blast analysis (http://blast.ncbi.nlm.
nih.gov/) and multiple sequence alignments, 25 samples aligned
with serotype 6A, 3 to serotype 6B, and none to serotype 6C.
Reference sequences used were: serotype 6A (GenBank accession
no. JF911497.1), 6B (GenBank accession no. JF911507.1), and 6C
(GenBank accession no. JF911510.1). In addition to SNP G584A
of Jin et al. [24], we noticed another SNP (G574T) that could be
used to differentiate the 6A/C from the 6B serotype. By using the
NEB cutter program (http://tools.neb.com/NEBcutter2/index.
php), we mapped the restriction site of the enzyme BsrI (New
England Biolabs), and showed distinct digestion patterns for the
two serotypes: three bands aligning with the molecular weights for
145, 69 and 59 bp for 6A/C serotype: two bands aligning with 214
and 59 bp for 6B serotype.
For RFLP analysis, 20 ml of each PCR product was digested
with BsrI for 4 h at 65uC. DNA fragments were resolved by
electrophoresis on a 2% agarose gel.
In the case of serotype 6A/C, the amplicons digested by BsrI
gave the 145 bp band, while the lower molecular weight bands 69
and 59 bp were seen as one band on the gel (Figure 1). In the case
of serotype 6B, the bands of 214 and 59 bp, were clearly
separated. Each DNA sample was analyzed at least in duplicate
against serotype 6A and 6B positive controls as revealed by
sequence analysis. The primers used for genotyping by PCR-
RFLP of the serotype 6A/C and 6B SNPs were the same as those
used for amplicon sequencing.
Results
Study Participation
Nasopharyngeal swabs were taken from 397 healthy children
aged 1 to 23 months; mean age was 11 months. 248 (62.5%) of the
children were less than 1 years old, 149 (37.5%) were between 1
and 2 years old. Gender distribution (Male: Female) was 1:1.
Vaccine PCV7 (containing serotypes: 4, 6B, 9V, 14, 18C, 19F, and
23F) was introduced in Palestine as a pilot trial since September
2010 in the following districts: Hebron, Bethlehem, Jericho and
Tubas. One (0.3%) child received one dose of vaccine during the
time preceding enrollment, 130/397 (32.7%) received two doses,
69/397 (17.4%) received three doses and 197/397 (49.6%)
children had not received the vaccine (Table 1). Strains of S.
pneumoniae were isolated from 221 of the 397 healthy children
surveyed, giving a total carrier rate of 55.7%, some of whom did
receive the PCV7 vaccine and some not. The distribution of
nasopharyngeal pneumococcal carrier rate among the West Bank
districts is shown in Table 1.
The pneumococcal carriage rate among children of different
ages was: 40.2% (33/87) in those 0-6 months; 62.5% (95/152)
.6–12 months; 53.8% (56/104) .12–18 months and 64.8% (35/
54) .18–24 months. The overall colonization rate among the
PCV7-vaccinated children was 61.5% (123/200) (Table 1). The
colonization rates among children who received either two or
three doses of vaccine were 60.8% (79/130) and 63.8% (44/69),
respectively, and among those unvaccinated 50.3% (99/197).
Antimicrobial resistance
Susceptibility to antimicrobial agents was tested on 211 (95.5%)
of the 221 isolates of S. pneumoniae (Table S1). Only 47/211
(22.3%) of them were fully susceptible to all the antibiotics tested,
58/211 (27.5%) were resistant to one of the antimicrobial agents,
34/211 (16.1%) were resistant to two, and 72/211 (34.1%) to
more than two.
Of the 211 pneumococcal isolates examined, 23 (10.9%) were
resistant to penicillin and 118 (55.9%) were intermediately
resistant. Higher resistance rates were noted for trimethoprim-
sulfamethoxazole, 97/211 (45.9%), and erythromycin, 64/213
(30.3%). None was resistant to cefotaxime and vancomycin.
Of the isolated bacterial strains of the serotypes 4, 6B, 9V, 14,
18C, 19F, and 23F found in the PCV7 vaccine that were
examined for antimicrobial susceptibility, 59/79 (75%), 49/79
(62.0%) and 23/79 (29%) were non-susceptible to two, three and
four antibiotics, respectively; whereas, of the bacterial strains of the
additional serotypes found in the PCV13 vaccine, 14/38 (37%), 7/
38 (18%) and 2/38 (5%) were not wholly or partially susceptible to
two, three and four antibiotics, respectively (Table S1 and S2).
Overall, the resistance of the isolates of S. pneumoniae to the
antibacterial agents tested did not appear to be directly correlated
with the childrens’ vaccination status (p = 0.079). However,
resistance of isolates to tetracycline and erythromycin did correlate
significantly (p = 0.026 and 0.012, respectively) with whether they
Figure 1. A representative DNA electrophoresis gel showing
the RFLP patterns of the serotypes 6A/C and 6B after BsrI
digestion of the amplified cps amplicon (273 bp) for isolates of
S. pneumonia of the serogroup 6. DNA was visualized in 2% agarose
gel: lane 1 100 bp ladder; lane 12 50 bp ladder. Lanes 2–4 and 7–8 S.
pneumonia serotype 6A/C patterns (yielding fragments of 145, 69 and
59 bp, with both smaller fragments showing as one thick band owing
to low separation). Lanes 5–6 and 9–11 S. pneumonia serotype 6B
(yielding fragments of 214 and 59 bp).
doi:10.1371/journal.pone.0082047.g001
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came from vaccinated and unvaccinated children. Isolates resistant
to one or other of these two drugs were associated with the
vaccinated group. In addition, percentage resistance of isolates of
the serotypes in the PCV7 vaccine was higher (38/41 (92.7%),
p,0.001) than that of isolates of the serotypes in the PCV13
vaccine (7.3%). Interestingly, resistance of isolates to tetracycline
correlated highly with the serotypes of the PCV7 vaccine (39/42
(92.9%), p,0.001).
Capsular Serotypes
Of the 221 isolates of S. pneumoniae, 191 (86.4%) were serotyped,
leaving 30 (13.6%) untyped. However, the untyped isolates were
sensitive to optochin and positive by the Real Time PCR-based
method employing the lytA target gene. This showed they were
isolates of S. pneumoniae. Isolates that did not typed with the test
primers of the multiplex PCR were considered to be untypeable
(NT). Altogether, 27 different serotypes were identified using the
sequential multiplex PCR reactions [23].
The most common strains were, in decreasing order, of the
serotypes: 6A, 19F, 23F, 6B, 14, 19A, 15B, 34 and 11A (Table 2).
Strains of the serotypes 6A, 19F, 23F and 6B were the most
prevalent (13.6%, 12.2%, 9.0% and 8.6%, respectively), followed
by strains of the serotypes 19A and 14, (both at 4.1%) and 15B/
15C and 34 (both at 3.6%). Among the carried isolates, 37.1%
were of the serotypes in the PCV7 vaccine and 56.1% were those
in the PCV13 vaccine (Table 2). Isolates carried by vaccinated
children, were of the serotypes 19F (13%), 23F (6.5%), 6B (8.1%)
and 14 (1.6%) in the PCV7 vaccine, in addition to which they also
carried isolates of the serotypes 6A (13.0%) and 19A (5.7%) in the
PCV13 vaccine. Those carried by non-vaccinated children were of
exactly the same serotypes but in different percentages, 11.2%,
12.2%, 9.2%, 7.1%, 14.3% and 2.0%, respectively.
Of the strains that were subjected to serotyping, 80.1% (113/
141) were non-susceptible to penicillin. Of these, 118 were
intermediately resistance and 23 were fully resistant. The common
serotypes of the fully resistant strains were 19F, 6A, 23F, 19A, 6B
and 24(A/B/F) while the common serotypes of the intermediately
resistant strains were 6B, 19F, 6A, 23F, 14 and 15B/C (Table S1
and S2).
Differentiation of Serogroup 6: 6A/C and 6B of S.
pneumoniae
All serogroup 6 samples (49) were analyzed by RFLP, 28 of
which were confirmed by sequencing, of which 25 were serotype
6A and 3 serotype 6B. The sequences obtained represent the 273
bp of the capsular gene region. The twenty-five 6A serotype
sequences were all identical to the 6A serotype reference sequence
(GenBank accession no. JF911497.1), while the three 6B serotype
sequences were all identical to the 6B serotype reference sequence
(GenBank accession no. JF911507.1), both of which are in the
National Center for Biotechnology Information Database (http://
www.ncbi.nih.gov/BLAST/). The two representative sequences
found were deposited in the GenBank database (6A serotype
accession no. KC834830 and 6B serotype KC834831).
As expected, fragment analysis, showed different patterns of
digestion for the 2 serotypes. Of the 49 samples, 30 belonged to the
serotype 6A/C and 19 to the serotype 6B. The results of samples
analyzed by the RFLP and the DNA-sequencing procedures
showed 100% agreement. Therefore, using the RFLP analysis
developed here, it was possible to differentiate between the
serotypes 6A/C and 6B, showing it to be a simple, rapid, direct
and reliable method (Figure 1).
Discussion
This is the first Palestinian national study documenting the
prevalence of the serotypes of strains S. pneumoniae carried in the
nasopharyngeal cavities of healthy children less than two years of
age before the introduction of PCV as part of a Palestinian NIP.
This study showed a carrier rate of 55.7%. This rate is similar to
the 50% among Palestinian children from the Gaza strip reported
by Regev-Yochay et al. [25]. In the neighboring region, Borer et
al. [26] found a carrier rate of 58% among children aged , 5
years in day care centers in Southern Israel. Similar carrier rates
were reported for Oman [27], Iran [28], Central Asia [29], the
Netherland [30], and Kenya [31]. However, it was relatively
higher compared to studies from other countries: Venezuela (28%)
[32], Greece (29.4%) [33], Hong Kong (19.4%) [34], Italy (8.6%)
[35], Europe as a whole region (21%) [36], the USA (20%) [12],
Turkey (22.5%) [37] and Northern Taiwan (20.8%) [38].
Table 1. Distribution of nasopharyngeal pneumococcal carrier rates in children ,2 years old from West Bank districts, including
vaccinations and colonization rates (%).
District
One
Dose
Two
Doses
Three
Doses
Not
Vaccinated Total
Positive S.
pneumoniae
Colonization
rate (%) PCV7 serotypes
Bethlehem 1 12 - - 13 7 53.8 0
Hebron - 59 - - 59 31 52.5 19F, 9V9A, 23F, 6B
Jericho - 39 23 - 62 41 66.1 19F, 9V9A, 23F, 6B
Tubas - 20 46 - 66 44 66.7 19F, 14, 23F, 6B
Ramallah - - - 41 41 14 34.1 19F, 14, 23F, 6B
Jerusalem - - - 15 15 7 46.6 23F, 6B, 14
Nablus - - - 52 52 25 48.1 19F, 14, 6B
Tulkarem - - - 24 24 13 54.2 19F, 23F, 6B
Qalqilia - - - 17 17 9 52.9 19F, 23F
Jenin - - - 39 39 23 58.9 23F, 4, 14, 6B
Salfeet - - - 9 9 8 77.7 19F, 18 (A/B/C/F)
Total 1 130 69 197 397 221 55.7 55.7
doi:10.1371/journal.pone.0082047.t001
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Isolated strains of the serotypes 6A, a serotype of a strain in the
PCV13 vaccine, 19F, 23F and 6B, serotypes of strains in the PCV7
vaccine, were most prevalent (13.6%, 12.2%, 9.0%, 8.6%,
respectively), followed by strains of the serotypes: 19A and 14,
(both 4.1%) and 15B/15C and 34 (both 3.6%). Worldwide
prevalence studies on the nasopharyngeal carriage of S. pneumoniae
have shown that, mostly, strains of the serotypes mentioned above
are involved but with differences in percentages among them
[12,29,36]. Of the strains carried by Palestinian children, 37.1%
were of the serotypes covered by the PCV7 vaccine and 56.1%
were those covered by the PCV13 vaccine. Clear difference was
noticed between the vaccinated and unvaccinated groups regard-
ing the serotypes 23F and 14 present in the PCV7 vaccine.
Changes in pneumococcal serotypes were also observed in
Portuguese vaccinated and unvaccinated populations [39]. While
as would be expected, strains of the other serotypes existing in the
PCV13 vaccine were found in equal percentages between
vaccinated and unvaccinated children. This study adds to a
previous Palestinian one [20] since it covers many geographical
areas and a more in-depth analysis of the prevalence of strains of
the serogroup 6. The previous study was restricted to a central
region of Palestine and treated all their isolates of the serogroup 6
as a single entity. Furthermore, the study done here was done on
healthy carriers. The incidence of pneumococcal disease is thought
to be tied to the prevalence of asymptomatic carriers. Also, strains
isolated from nasopharyngeal cavities can be used as determine
serotype distribution and predict drug resistance. This, in turn,
should improve the efficacy of treatment and vaccination.
The data presented here on the serotypes of carried strains,
together with the data previously reported by Kattan et al. [20],
Table 2. Serotype frequencies of strains of S. pneumoniae isolated from nasopharyngeal samples and their distribution according
to children’ vaccination status.
Serotype Total Number (%) Vaccination status
PCV7 serotypes Vaccinated group Unvaccinated group
19F 27 (12.2) 16 (13.0) 11 (11.2)
23F 20 (9.0) 8 (6.5) 12 (12.2)
6B 19 (8.6) 10 (8.1) 9 (9.2)
14 9 (4.1) 2 (1.6) 7 (7.1)
9V/9A* 4 (1.8) 4 (3.3) 0 (0)
4 2 (0.9) 0 (0) 2 (2.0)
18A/B/C/F* 1 (0.4) 0 (0) 1 (1.0)
Additional serotypes in PCV13
6A 30 (13.6) 16 (13.0) 14 (14.3)
19A 9 (4.1) 7 (5.7) 2 (2.0)
3 2 (0.9) 1 (0.8) 1 (1.0)
1 1 (0.4) 0 (0) 1 (1.0)
Other vaccine Serotypes#
15B/15C 8 (3.6) 5 (4.1) 3 (3.1)
11A/11D 7 (3.2) 4 (3.3) 3 (3.1)
10A 5 (2.3) 3 (2.4) 2 (2.0)
22F/22A 3 (1.4) 2 (1.6) 1 (1.0)
33F/33A/37 2 (0.9) 2 (1.6) 0 (0)
9N/9L 1 (0.4) 1 (0.8) 0 (0)
Other Serotypes
34 8 (3.6) 7 (5.7) 1 (1.0)
15A/15F 5 (2.3) 3 (2.4) 2 (2.0)
21 5 (2.3) 3 (2.4) 2 (2.0)
35B 4 (1.8) 3 (2.4) 1 (1.0)
38/25F/25A 4 (1.8) 3 (2.4) 1 (1.0)
7C/7B/40 4 (1.8) 2 (1.6) 2 (2.0)
24 A/B/F 3 (1.4) 1 (0.8) 2 (2.0)
35F/47F 3 (1.4) 3 (3.1) 3 (3.1)
13 3 (1.4) 1 (1.0) 2 (2.0)
23A 2 (0.9) 0 (0) 2 (2.0)
Nontypeable (Not Determined) 30 (13.6) 19 (15.4) 11 (11.2)
Total 221 (100) 123 (55.7) 98 (44.3)
*PCVs do not offer protection against all serotypes of serogroup 9 or 18.
#Serotypes that were not covered in the protein conjugate vaccines, PCV7 and PCV13, but they are in the PCV23 vaccine.
doi:10.1371/journal.pone.0082047.t002
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provides Palestinian Health Authorities with strong scientific
evidence to endorse ending using the PCV7 vaccine and
substituting it with the PCV13 vaccine because of the extra
strains serotypes it protects against, providing an additional 19.0%
serotype coverage. Congruently, results obtained from a carriage
study on healthy Israeli children aged below 36 months showed
the added benefit of an extended serotype coverage by the PCV13
vaccine over the PCV7 vaccine of 21%, raising it from 46% to
67% [40]. Employing the PCV13 vaccine increases the cross-
protective spectrum, at least against strains of the serotypes 6A,
19A, 3 and 1, which were also mentioned by Kattan et al., and are
also responsible for IPD among Palestinian children [20]. The
results from testing antimicrobial susceptibility of the strains of S.
pneumoniae isolated from the Palestinian children in relation to the
strain’s serotypes, as mentioned above and discussed below, also
support recommending using the PCV13 vaccine in the NIP in the
West Bank.
For many years, penicillin has been the drug of choice against
pneumococcal infections. However, microbial resistant has
increased over past decades [12,13,41]. Here, resistance to
penicillin was demonstrated with a non-susceptibility rate of
66.8% of the pneumococcal isolates examined (Table S2), which
agrees other studies [26,27,34,40]. As the prescribing and sale of
antibiotics is largely locally unregulated, these rates are expected.
The carriage of increasingly drug-resistant strains of S. pneumoniae
by individuals could lead to the increased transmission of resistant
pneumococcal disease at the community and national level. Also,
these results should discourage physicians from using penicillin as
empirical treatment for pneumococcal infections, particularly for
invasive ones. In this study, the six most prevalent serotypes, 19F,
6A, 23F, 6B, 19A and 14, represent more than half (51.6%) of the
pneumococcal strains encountered, and they are predominantly
(80.8%) non-susceptible to penicillin. The recent study by Kattan
et al. of children from the West Bank hospitalized with IPD caused
by strains of S. pneumoniae identified 49 cases (40.8%) infected with
strains of these serotypes [20]. Of all the serotypes covered by
these two vaccines, the serotypes 19F, 6A, 23F, 6B, 19A, 14 and
9V are associated with the highest rate of penicillin non-
susceptibility of the strains. Both vaccines, PCV7 and PCV13,
contain components with some or all of these 7 serotypes, and 68
(48.2%) of the 141 penicillin resistant isolates possessed the
serotypes in the PCV7 vaccine. An additional 18.4% of the 141
penicillin resistant isolates would accrue if the extra serotypes in
the PCV13 vaccine were included. Regarding the examination of
the efficacy of erythromycin, isolates of the serotypes 6B, 19F, 23F,
6A, 14, 19A, and 9V were associated with erythromycin resistant
strains and the serotypes in the PCV7 and PCV13 vaccines cover
60 (54.5%) and 87 (79.0%), of the 110 erythromycin resistant
isolates, respectively. Resistance to two antibiotics was observed in
75% and 37% of the isolates bearing the serotypes in the PCV7
and PCV13 vaccines, respectively.
In addition, there was a high degree of microbial resistance,
against three and four antibacterial drugs by isolates with the
serotypes in the PCV7 vaccine (Table S1). Resistance to
tetracycline and erythromycin showed a significant correlation
(p = 0.026 and 0.012, respectively) to vaccination status and
bacterial isolates from the vaccinated group appeared to be more
resistant to both drugs than isolates from the unvaccinated.
Serogroup 6 consists of strains of the serotypes 6A and 6B, and
the more recently discovered serotypes 6C and 6D [10,42], some
of which are of importance in carriage and in causing invasive
disease [43,44]. Different molecular methods for sub-typing strains
in serogroup 6 into the serotypes 6A, 6B, 6C and 6D have been
described [24,45]. However, one requires sophisticated equipment
and training and one do not enable easy differentiation.
Serological determination by the quellung reaction (capsular
swelling) is considered the gold standard for serotyping. This
method is limited as antisera are very expensive, good technical
skill is required and interpretation of results is complicated. Here,
a new PCR-RFLP method was developed and optimized that
enabled the differentiation of the serotypes 6A/C and 6B. To our
knowledge, no other RFLP assay for differentiating the serotypes
6A 6B and 6C has been developed and published. This procedure
is simple, fast, reliable and less costly than sequencing, and can be
used in any molecular laboratory.
Conclusions
1. A high carrier rate of S. pneumoniae was observed in healthy
Palestinian children.
2. The main strain serotypes were 19F, 23F, 14, 19A and, also,
6A/C and 6B that were differentiated using a new PCR-RFLP
method developed and optimized in our laboratory.
3. High antibiotic resistance was revealed among the strains of S.
pneumoniae isolated from nasopharyngeal cavities.
4. The high carrier rate of S. pneumoniae in the asymptomatic
children combined with the results from testing antimicrobial
susceptibility of the strains of S. pneumoniae isolated from their
nasopharyngeal cavities, and the relationship of the isolates’
serotypes compared with the serotypes in pneumococcal
vaccines supports recommending using the PCV13 rather
than the PCV7 vaccine in the NIP in the West Bank Region.
Supporting Information
Table S1 Antibiotic susceptibility testing* results by
serotype distribution.
(DOCX)
Table S2 Antibiotics not susceptible (Both intermediate
and resistant) to one or more antibiotics in regards to
PCV Serotypes.
(DOCX)
Acknowledgments
We thank all the physicians, nurses, and subjects who participated in this
study. Also, we thank the laboratory technical staff at the CPHL for their
assistance and support.
Author Contributions
Conceived and designed the experiments: AN AR ZA. Performed the
experiments: AN ISH NS. Analyzed the data: AN ISH NS. Contributed
reagents/materials/analysis tools: AN ZA NS. Wrote the paper: AN IS.
References
1. Brugger SD, Hathaway LJ, Muhlemann K (2009) Detection of Streptococcus
pneumoniae strain cocolonization in the nasopharynx. J Clin Microbiol 47:
1750–1756.
2. Dagan R, Givon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, et al. (2002)
Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after
administration of a 9-valent pneumococcal conjugate vaccine to toddlers
attending day care centers. J Infect Dis 185: 927–936.
S. pneumoniae Serotypes in Palestine
PLOS ONE | www.plosone.org 6 December 2013 | Volume 8 | Issue 12 | e82047
3. WHO (2007) Pneumococcal conjugate vaccine for childhood immunization—
WHO position paper. Wkly Epidemiol Rec 82: 93–104.
4. O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, et al. (2009)
Burden of disease caused by Streptococcus pneumoniae in children younger
than 5 years: global estimates. Lancet 374: 893–902.
5. Cardozo DM, Nascimento-Carvalho CM, Souza FR, Silva NM (2006)
Nasopharyngeal colonization and penicillin resistance among pneumococcal
strains: a worldwide 2004 update. Braz J Infect Dis 10: 293–304.
6. Lin WJ, Lo WT, Chou CY, Chen YY, Tsai SY, et al. (2006) Antimicrobial
resistance patterns and serotype distribution of invasive Streptococcus
pneumoniae isolates from children in Taiwan from 1999 to 2004. Diagn
Microbiol Infect Dis 56: 189–196.
7. Malfroot A, Verhaegen J, Dubru JM, Van Kerschaver E, Leyman S (2004) A
cross-sectional survey of the prevalence of Streptococcus pneumoniae nasopha-
ryngeal carriage in Belgian infants attending day care centres. Clin Microbiol
Infect 10: 797–803.
8. Sjostrom K, Blomberg C, Fernebro J, Dagerhamn J, Morfeldt E, et al. (2007)
Clonal success of piliated penicillin nonsusceptible pneumococci. Proc Natl Acad
Sci U S A 104: 12907–12912.
9. Arai S, Konda T, Wad A, Matsunaga Y, Okabe N, et al. (2001) Use of
antiserum-coated latex particles for serotyping Streptococcus pneumoniae.
Microbiol Immunol 45: 159–162.
10. kamerling JP (2000) Streptococcus pneumoniae: molecular biology and
mechanisms of disease. In: Tomasz A, editor. Pneumococcal polysaccharides:
a chemical view. Larchmont, NY: Mary Ann Liebert. pp. 81–114.
11. Melin M, Trzcinski K, Meri S, Kayhty H, Vakevainen M (2010) The capsular
serotype of Streptococcus pneumoniae is more important than the genetic
background for resistance to complement. Infect Immun 78: 5262–5270.
12. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, et al. (2007)
Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine
(PCV7) serotypes in the United States during the era of widespread PCV7
vaccination, 1998-2004. J Infect Dis 196: 1346–1354.
13. McIntosh ED, Reinert RR (2011) Global prevailing and emerging pediatric
pneumococcal serotypes. Expert Rev Vaccines 10: 109–129.
14. Harboe ZB, Valentiner-Branth P, Benfield TL, Christensen JJ, Hjuler T, et al.
(2008) Estimated effect of pneumococcal conjugate vaccination on invasive
pneumococcal disease and associated mortality, Denmark 2000-2005. Vaccine
26: 3765–3771.
15. Kaltoft MS, Skov Sorensen UB, Slotved HC, Konradsen HB (2008) An easy
method for detection of nasopharyngeal carriage of multiple Streptococcus
pneumoniae serotypes. J Microbiol Methods 75: 540–544.
16. Sahni V, Naus M, Hoang L, Tyrrell GJ, Martin I, et al. (2012) The
epidemiology of invasive pneumococcal disease in British Columbia following
implementation of an infant immunization program: increases in herd immunity
and replacement disease. Can J Public Health 103: 29–33.
17. Aristegui J, Bernaola E, Pocheville I, Garcia C, Arranz L, et al. (2007) Reduction
in pediatric invasive pneumococcal disease in the Basque Country and Navarre,
Spain, after introduction of the heptavalent pneumococcal conjugate vaccine.
Eur J Clin Microbiol Infect Dis 26: 303–310.
18. Feikin DR, Klugman KP (2002) Historical changes in pneumococcal serogroup
distribution: implications for the era of pneumococcal conjugate vaccines. Clin
Infect Dis 35: 547–555.
19. Jacobs MR, Good CE, Bajaksouzian S, Windau AR (2008) Emergence of
Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in
Cleveland, Ohio, in relation to introduction of the protein-conjugated
pneumococcal vaccine. Clin Infect Dis 47: 1388–1395.
20. Kattan R, Abu Rayyan A, Zheiman I, Idkeidek S, Baraghithi S, et al. (2011)
Serotype distribution and drug resistance in Streptococcus pneumoniae,
Palestinian Territories. Emerg Infect Dis 17: 94–96.
21. McAvin JC, Reilly PA, Roudabush RM, Barnes WJ, Salmen A, et al. (2001)
Sensitive and specific method for rapid identification of Streptococcus
pneumoniae using real-time fluorescence PCR. J Clin Microbiol 39: 3446–3451.
22. CLSI (2012) Performance standards for antimicrobial susceptibility testing.
M100–S22.
23. Pai R, Gertz RE, Beall B (2006) Sequential multiplex PCR approach for
determining capsular serotypes of Streptococcus pneumoniae isolates. J Clin
Microbiol 44: 124–131.
24. Jin P, Xiao M, Kong F, Oftadeh S, Zhou F, et al. (2009) Simple, accurate,
serotype-specific PCR assay to differentiate Streptococcus pneumoniae serotypes
6A, 6B, and 6C. J Clin Microbiol 47: 2470–2474.
25. Regev-Yochay G, Abullaish I, Malley R, Shainberg B, Varon M, et al. (2012)
Streptococcus pneumoniae carriage in the Gaza strip. PLoS One 7: e35061.
26. Borer A, Meirson H, Peled N, Porat N, Dagan R, et al. (2001) Antibiotic-
resistant pneumococci carried by young children do not appear to disseminate to
adult members of a closed community. Clin Infect Dis 33: 436–444.
27. Al-Yaqoubi MM, Elhag KM (2011) Serotype Prevalence and Penicillin-
susceptibility of Streptococcus pneumoniae in Oman. Oman Med J 26: 43–47.
28. Sanaei Dashti A, Abdinia B, Karimi A (2012) Nasopharyngeal carrier rate of
Streptococcus pneumoniae in children: serotype distribution and antimicrobial
resistance. Arch Iran Med 15: 500–503.
29. Factor SH, LaClaire L, Bronsdon M, Suleymanova F, Altynbaeva G, et al.
(2005) Streptococcus pneumoniae and Haemophilus influenzae type B Carriage,
Central Asia. Emerg Infect Dis 11: 1476–1479.
30. Bogaert D, Engelen MN, Timmers-Reker AJ, Elzenaar KP, Peerbooms PG, et
al. (2001) Pneumococcal carriage in children in The Netherlands: a molecular
epidemiological study. J Clin Microbiol 39: 3316–3320.
31. Abdullahi O, Karani A, Tigoi CC, Mugo D, Kungu S, et al. (2012) The
prevalence and risk factors for pneumococcal colonization of the nasopharynx
among children in Kilifi District, Kenya. PLoS One 7: e30787.
32. Quintero B, Araque M, van der Gaast-de Jongh C, Escalona F, Correa M, et al.
(2011) Epidemiology of Streptococcus pneumoniae and Staphylococcus aureus
colonization in healthy Venezuelan children. Eur J Clin Microbiol Infect Dis 30:
7–19.
33. Katsarolis I, Poulakou G, Analitis A, Matthaiopoulou I, Roilides E, et al. (2009)
Risk factors for nasopharyngeal carriage of drug-resistant Streptococcus
pneumoniae: data from a nation-wide surveillance study in Greece. BMC
Infect Dis 9: 120.
34. Chiu SS, Ho PL, Chow FK, Yuen KY, Lau YL (2001) Nasopharyngeal carriage
of antimicrobial-resistant Streptococcus pneumoniae among young children
attending 79 kindergartens and day care centers in Hong Kong. Antimicrob
Agents Chemother 45: 2765–2770.
35. Marchisio P, Esposito S, Schito GC, Marchese A, Cavagna R, et al. (2002)
Nasopharyngeal carriage of Streptococcus pneumoniae in healthy children:
implications for the use of heptavalent pneumococcal conjugate vaccine. Emerg
Infect Dis 8: 479–484.
36. Isaacman DJ, McIntosh ED, Reinert RR (2010) Burden of invasive
pneumococcal disease and serotype distribution among Streptococcus pneumo-
niae isolates in young children in Europe: impact of the 7-valent pneumococcal
conjugate vaccine and considerations for future conjugate vaccines. Int J Infect
Dis 14: e197–209.
37. Ozdemir B, Beyazova U, Camurdan AD, Sultan N, Ozkan S, et al. (2008)
Nasopharyngeal carriage of Streptococcus pneumoniae in healthy Turkish
infants. J Infect 56: 332–339.
38. Lo WT, Wang CC, Yu CM, Chu ML (2003) Rate of nasopharyngeal carriage,
antimicrobial resistance and serotype of Streptococcus pneumoniae among
children in northern Taiwan. J Microbiol Immunol Infect 36: 175–181.
39. Sa-Leao R, Nunes S, Brito-Avo A, Frazao N, Simoes AS, et al. (2009) Changes
in pneumococcal serotypes and antibiotypes carried by vaccinated and
unvaccinated day-care centre attendees in Portugal, a country with widespread
use of the seven-valent pneumococcal conjugate vaccine. Clin Microbiol Infect
15: 1002–1007.
40. Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R (2009) Serotype
coverage of invasive and mucosal pneumococcal disease in Israeli children
younger than 3 years by various pneumococcal conjugate vaccines. Pediatr
Infect Dis J 28: 277–282.
41. Scheifele D, Halperin S, Pelletier L, Talbot J, Lovgren M, et al. (2001) Reduced
susceptibility to penicillin among pneumococci causing invasive infection in
children - Canada, 1991 to 1998. Can J Infect Dis 12: 241–246.
42. Jin P, Kong F, Xiao M, Oftadeh S, Zhou F, et al. (2009) First report of putative
Streptococcus pneumoniae serotype 6D among nasopharyngeal isolates from
Fijian children. J Infect Dis 200: 1375–1380.
43. Hausdorff WP, Bryant J, Paradiso PR, Siber GR (2000) Which pneumococcal
serogroups cause the most invasive disease: implications for conjugate vaccine
formulation and use, part I. Clin Infect Dis 30: 100–121.
44. Nahm MH, Lin J, Finkelstein JA, Pelton SI (2009) Increase in the prevalence of
the newly discovered pneumococcal serotype 6C in the nasopharynx after
introduction of pneumococcal conjugate vaccine. J Infect Dis 199: 320–325.
45. Pai R, Limor J, Beall B (2005) Use of pyrosequencing to differentiate
Streptococcus pneumoniae serotypes 6A and 6B. J Clin Microbiol 43: 4820–
4822.
S. pneumoniae Serotypes in Palestine
PLOS ONE | www.plosone.org 7 December 2013 | Volume 8 | Issue 12 | e82047
